Citadel Advisors LLC acquired a new position in Replimune Group Inc (NASDAQ:REPL) during the third quarter, according to its most recent 13F filing with the SEC. The firm acquired 389,535 shares of the company’s stock, valued at approximately $6,272,000. Citadel Advisors LLC owned 1.23% of Replimune Group at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp purchased a new position in shares of Replimune Group in the 3rd quarter worth about $319,000. Dean Capital Investments Management LLC purchased a new position in shares of Replimune Group in the 3rd quarter worth about $637,000. Franklin Resources Inc. purchased a new position in shares of Replimune Group in the 3rd quarter worth about $1,179,000. Victory Capital Management Inc. purchased a new position in shares of Replimune Group in the 3rd quarter worth about $2,066,000. Finally, BlackRock Inc. purchased a new position in shares of Replimune Group in the 3rd quarter worth about $6,411,000. Institutional investors own 55.75% of the company’s stock.

Several equities research analysts recently commented on REPL shares. BMO Capital Markets started coverage on Replimune Group in a report on Tuesday, August 14th. They set an “outperform” rating and a $31.00 target price on the stock. Leerink Swann started coverage on Replimune Group in a report on Tuesday, August 14th. They set an “outperform” rating and a $25.00 target price on the stock. Zacks Investment Research upgraded Replimune Group from a “sell” rating to a “hold” rating in a report on Wednesday, November 7th. Finally, JPMorgan Chase & Co. started coverage on Replimune Group in a report on Tuesday, August 14th. They set an “overweight” rating and a $26.00 target price on the stock.

Shares of NASDAQ:REPL opened at $14.69 on Friday. Replimune Group Inc has a one year low of $10.52 and a one year high of $23.55.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Wednesday, November 14th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.06). As a group, research analysts anticipate that Replimune Group Inc will post -1.21 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://theolympiareport.com/2018/12/07/citadel-advisors-llc-acquires-new-holdings-in-replimune-group-inc-repl.html.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

Featured Article: Systematic Risk and Investors

Want to see what other hedge funds are holding REPL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Replimune Group Inc (NASDAQ:REPL).

Institutional Ownership by Quarter for Replimune Group (NASDAQ:REPL)

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.